3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
2
Phase 4
1
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
58
Breast Neoplasms
43
Prostatic Neoplasms
32
Lung Neoplasms
29
Multiple Myeloma
23
Neoplasms
22
Parkinson Disease 4, Autosomal Dominant Lewy Body
17
Ovarian Neoplasms
17
Colorectal Neoplasms
17
Neoplasm Metastasis
16
Leukemia, Lymphocytic, Chronic, B-Cell
16
Carcinoma, Renal Cell
14
Pancreatic Neoplasms
13
Endometrial Neoplasms
12
Small Cell Lung Carcinoma
11
Urinary Bladder Neoplasms
10
Stomach Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Myasthenia Gravis
9
Lymphoma, Follicular
9
Leukemia, Myeloid, Acute
9
Fallopian Tube Neoplasms
9
Non-Muscle Invasive Bladder Neoplasms
8
Colonic Neoplasms
8
Burkitt Lymphoma
7
Recurrence
6
Lymphoma, Mantle-Cell
6
Esophageal Neoplasms
6
Adenocarcinoma
6
Triple Negative Breast Neoplasms
5
Interventions
ibrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Bronchiolitis Obliterans Syndrome
×
30 days
×
Clear all
NCT01804686
2026-06-05
CAN3001
Janssen Research & Development, LLC
Phase 3
Recruiting
700 enrolled